AGIOS PHARMACEUTICALS, INC. Current Liabilities
AGIOS PHARMACEUTICALS, INC. (AGIO) had Current Liabilities of $70.22 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Liabilities, Current $70.22M.
- 2026-03-31: Liabilities, Current $58.84M.
- 2025-12-31: Liabilities, Current $82.21M.
- 2025-09-30: Liabilities, Current $74.76M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $70.22M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $58.84M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $82.21M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $74.76M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $70.41M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $52.37M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $81.16M 10-K · filed 2026-02-12 |
| 2024-09-30 | $119.45M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $62.64M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $51.69M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $67.95M 10-K · filed 2025-02-13 |
| 2023-09-30 | $58.42M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $55.14M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $45.11M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $62.63M 10-K · filed 2024-02-15 |
| 2022-09-30 | $53.60M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $48.40M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $45.79M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $59.83M 10-K · filed 2023-02-23 |
| 2021-09-30 | $57.90M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $60.65M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $96.50M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $94.39M 10-K · filed 2022-02-24 |
| 2020-09-30 | $69.77M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $64.35M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $69.86M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $92.89M 10-K · filed 2021-02-25 |
| 2019-09-30 | $92.43M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $89.50M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $80.91M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $93.50M 10-K · filed 2021-02-25 |
| 2018-09-30 | $84.75M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $84.87M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $74.70M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $94.94M 10-K · filed 2019-02-14 |
| 2017-09-30 | $88.11M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $93.65M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $82.43M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $88.43M 10-K · filed 2018-02-14 |
| 2016-09-30 | $78.00M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $67.26M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $45.05M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $52.89M 10-K · filed 2017-02-16 |
| 2015-09-30 | $49.76M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $45.20M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $36.38M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $61.09M 10-K · filed 2016-02-26 |
| 2014-09-30 | $35.08M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $44.64M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $34.08M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $36.93M 10-K · filed 2015-02-24 |
| 2013-09-30 | $37.38M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $36.98M 10-Q · filed 2013-09-05 |
| 2012-12-31 | $35.11M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |